Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2014

View Archived Issues

Full year report - 2013 was a successful year for Lundbeck

Technetium Tc 99m trofolastat accurately detects cancer in the prostate gland

Takeda Pharmaceutical advances key programs in third quarter of fiscal 2013

ARADES and ARAFOR trial data reported for ODM-201 in prostate cancer

Protalex reports data from phase Ib trial of PRTX-100 in active rheumatoid arthritis

arGEN-X begins phase Ib study of ARGX-111

GlaxoSmithKline reports discovery of selective androgen receptor modulators

First-in-human clinical evaluation of a sustained-release exenatide for the treatment of diabetes

Ganymed Pharmaceuticals begins phase I/II trial of IMAB-027 in advanced ovarian cancer

Merck & Co. discloses new HIV prodrugs

Regeneron Pharmaceuticals and Bayer HealthCare report 2-year data from VISTA-DME trial

New targeted immunotherapy compounds designed by Shanghai Birdie Biotech

EMA's Committee for Orphan Medicinal Products issues positive opinion on Arikace

Biogen Idec patent divulges novel S1P modulating agents

Merck & Co. reports development of DPP IV inhibitors for diabetes

Sarepta Therapeutics reports safety data from phase I study of AVI-7288

Study of Repros' Androxal shows sustained effect in men with secondary hypogonadism

Aduro BioTech begins phase IIb ECLIPSE trial in patients with pancreatic cancer

Audion Therapeutics and Lilly to develop hearing loss treatments

Results from preliminary safety study evaluating trebananib plus abiraterone in patients with CRPC

Gilead submits NDA for fixed-dose combination tablet for HCV infection

Lipocine begins dosing in pivotal SOAR study

Oramed submits phase IIa protocol to FDA for oral insulin capsule

Scancell's SCIB-1 receives FDA orphan drug status for metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...